[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 15 of about 15
1. Shamberger RC, Ritchey ML, Haase GM, Bergemann TL, Loechelt-Yoshioka T, Breslow NE, Green DM: Intravascular extension of Wilms tumor. Ann Surg; 2001 Jul;234(1):116-21
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intravascular extension of Wilms tumor.
  • OBJECTIVE: To define the incidence and manifestations of and optimal therapy for children with intravascular extension of Wilms tumor.
  • METHODS: Children on a collaborative study of Wilms tumor who had intravascular extension into the inferior vena cava (IVC) or atrium were identified.
  • RESULTS: One hundred sixty-five of 2,731 patients had intravascular extension of Wilms tumor.
  • Sixty-nine had received preoperative therapy (55 with IVC extension and 14 with atrial extension) for a median of 8 weeks.
  • Complications during preoperative chemotherapy were seen in five patients (tumor embolism and tumor progression in one each, and three with adult respiratory distress syndrome, one of which was fatal).
  • The intravascular extension of the tumor regressed in 39 of 49 children with comparable pre- and posttherapy radiographic studies, including 7 of 12 in whom the tumor regressed from an atrial location, thus obviating the need for cardiopulmonary bypass.
  • Surgical complications occurred in 36.7% of the children in the atrial group and 17.2% in the IVC group.
  • The frequency of surgical complications was 26% in the primary resection group versus 13.2% in children with preoperative therapy.
  • When all the complications of therapy were considered, including those that occurred during the interval of preoperative chemotherapy (one of the five also had a surgical complication), the incidence of complications among those receiving preoperative therapy was not statistically different from the incidence among those who underwent primary resection.
  • The difference in 3-year relapse-free survival (76.9% for 165 patients with intravascular extension, 80.3% for 1,622 patients with no extension) was not statistically significant whether or not it was adjusted for stage and histology.
  • CONCLUSIONS: Preoperative treatment of these children may facilitate resection by decreasing the extent of the tumor thrombus, but the overall frequency of complications is similar in both groups.

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1970 Aug;26(2):338-40 [4317965.001]
  • [Cites] J Urol. 1988 Nov;140(5 Pt 2):1113-8 [2846897.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1986 Spring;8(1):75-8 [3013040.001]
  • [Cites] Med Pediatr Oncol. 1992;20(1):61-3 [1309207.001]
  • [Cites] J Pediatr Surg. 1992 Jul;27(7):912-5 [1322458.001]
  • [Cites] Surg Gynecol Obstet. 1992 Dec;175(6):507-14 [1333095.001]
  • [Cites] Cancer. 1993 Jun 15;71(12):4104-10 [8389661.001]
  • [Cites] J Urol. 1993 Sep;150(3):933-5 [8393945.001]
  • [Cites] J Pediatr Surg. 1994 Feb;29(2):229-31 [8176597.001]
  • [Cites] Pediatr Hematol Oncol. 1994 Sep-Oct;11(5):535-40 [7530031.001]
  • [Cites] Med Pediatr Oncol. 1996 Apr;26(4):268-71 [8600341.001]
  • [Cites] Br J Urol. 1996 Nov;78(5):772-6 [8976777.001]
  • [Cites] Postgrad Med J. 1996 Dec;72(854):749-50 [9015469.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):237-45 [9440748.001]
  • [Cites] J Urol. 1986 Jul;136(1 Pt 2):312-7 [2425100.001]
  • [Cites] Ann Surg. 1986 Dec;204(6):693-7 [3024596.001]
  • [Cites] Urology. 1982 Jan;19(1):55-60 [6277066.001]
  • (PMID = 11420491.001).
  • [ISSN] 0003-4932
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-42326
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC1421956
  •  go-up   go-down


2. Tsuchiya T, Hiramatsu K, Tanaka H, Machiki Y, Sakuragawa T, Otsuji H, Hara T, Kimura A, Yoshida K, Hosoya J, Kojima T, Kato K: [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases]. Gan To Kagaku Ryoho; 2009 Dec;36(13):2641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A Case of gastric endocrine cell carcinoma successfully treated by FU plus irinotecan(CPT-11)adjuvant therapy against recurrent metastases].
  • A case of gastric endocrine cell carcinoma successfully treated by FU (5-FU/UFT) +irinotecan (CPT-11) adjuvant therapy against recurrent metastases is reported with some discussion.
  • A 69-year-old man was admitted to our hospital with severe anemia.
  • He was diagnosed with advanced gastric cancer, T3N1H0P0M0, Stage IIIa.
  • Seven months after operation, recurrent liver metastases with tumor embolism of the portal vein were revealed by enhanced CT examination.
  • FU (5-FU/UFT) +CPT-11 was done as the first-line adjuvant chemotherapy.
  • Metastatic lesion of the liver and portal vein tumor embolism was decreased.
  • Tumor marker CA19-9 level was also decreased and within normal limits.
  • This therapy was evaluated as a partial response (PR) in twelve months and the patient died three years and eight months after operation.
  • Gastric endocrine cell carcinoma is known as a potentially highly malignant tumor.
  • But in our case FU+CPT-11 controlled growth of the recurrent tumor.
  • Based on this finding, we recommend adjuvant chemotherapy by FU+CPT-11 for gastric endocrine cell carcinoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Stomach Neoplasms / therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Chemotherapy, Adjuvant. Fluorouracil / administration & dosage. Gastrectomy. Humans. Lymph Node Excision. Male. Neoplasm Metastasis. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20009471.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Phytogenic; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Hiraki M, Sato S, Kai K, Ohtsuka T, Kohya N, Kitajima Y, Nakafusa Y, Tokunaga O, Miyazaki K: A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study. Clin J Gastroenterol; 2009 Oct;2(5):331-337
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study.
  • A 67-year-old male with advanced gastric cancer and lymph node metastasis as well as a tumor embolus in the portal vein was treated by S-1/cisplatin therapy.
  • After one course of chemotherapy, the patient showed stable disease; the serum level of alpha-fetoprotein also decreased to 626 ng/ml after a transient increase, and therefore reduction surgery was performed.
  • A total gastrectomy with a distal pancreatectomy, splenectomy, and regional lymph node dissection was performed.
  • There were no metastatic foci in the resected lymph nodes, presumably due to the preoperative chemotherapy.
  • S-1/cisplatin therapy was continued after the operation to treat the remaining tumor embolus in the portal vein.
  • After one course of this therapy, the tumor embolus disappeared.
  • Therefore, the chemotherapy was changed to paclitaxel monotherapy.
  • The ortate phosphoribosyltransferase expression was strongly positive, and the good outcome in this case may have been associated with this result.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:71-81 [12775024.001]
  • [Cites] World J Surg Oncol. 2007 Jul 16;5:79 [17634124.001]
  • [Cites] Hepatogastroenterology. 2006 May-Jun;53(69):338-41 [16795967.001]
  • [Cites] Hepatogastroenterology. 2005 Jan-Feb;52(61):326-8 [15783061.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 [10655437.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2008 Oct;105(10):1489-95 [18840987.001]
  • [Cites] Acta Gastroenterol Belg. 2006 Jul-Sep;69(3):330-7 [17168134.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):176-82 [8558194.001]
  • [Cites] Surg Today. 2002;32(5):429-33 [12061695.001]
  • [Cites] Cancer Chemother Pharmacol. 2005 Aug;56(2):138-44 [15827767.001]
  • [Cites] Lancet Oncol. 2008 Mar;9(3):215-21 [18282805.001]
  • [Cites] Anticancer Res. 2004 Jul-Aug;24(4):2495-501 [15330204.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):416-9 [9708646.001]
  • [Cites] Intern Med. 2000 Mar;39(3):223-7 [10772124.001]
  • [Cites] Cancer. 1998 Oct 1;83(7):1300-6 [9762929.001]
  • [Cites] Radiology. 1990 Mar;174(3 Pt 1):811-4 [1689502.001]
  • [Cites] Kurume Med J. 2002;49(3):157-60 [12471731.001]
  • [Cites] Dig Surg. 2002;19(5):359-65; discussion 365 [12435906.001]
  • [Cites] Gastric Cancer. 2003;6 Suppl 1:66-70 [12775023.001]
  • [Cites] Am J Gastroenterol. 1992 Mar;87(3):321-5 [1371637.001]
  • [Cites] Gastric Cancer. 1998 Dec;1(1):10-24 [11957040.001]
  • [Cites] Surg Today. 2004;34(9):784-7 [15338356.001]
  • [Cites] Cancer Lett. 2007 Dec 8;258(1):45-54 [17892912.001]
  • [Cites] Gan To Kagaku Ryoho. 2001 Dec;28(13):2079-82 [11791389.001]
  • [Cites] Oncology. 2004;66(6):445-9 [15452373.001]
  • [Cites] Oncol Rep. 2006 Oct;16(4):721-7 [16969485.001]
  • [Cites] Hepatogastroenterology. 2007 Jun;54(76):1302-4 [17629094.001]
  • [Cites] J Gastroenterol. 2003;38(6):540-7 [12825129.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 2005 Dec;102(12):1523-8 [16372769.001]
  • [Cites] Oncology. 2004;66(3):226-33 [15218314.001]
  • [Cites] Intern Med. 2004 Feb;43(2):106-10 [15005251.001]
  • [Cites] Clin Cancer Res. 1998 Apr;4(4):1013-9 [9563897.001]
  • [Cites] Int J Cancer. 2006 Oct 15;119(8):1927-33 [16736497.001]
  • [Cites] Gan To Kagaku Ryoho. 2008 Feb;35(2):299-301 [18281769.001]
  • [Cites] Gastric Cancer. 2001;4(1):43-52 [11706627.001]
  • [Cites] Gan To Kagaku Ryoho. 2005 Jun;32(6):855-8 [15984531.001]
  • [Cites] Surg Today. 2002;32(12 ):1075-80 [12541026.001]
  • (PMID = 26192608.001).
  • [ISSN] 1865-7257
  • [Journal-full-title] Clinical journal of gastroenterology
  • [ISO-abbreviation] Clin J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Keywords] NOTNLM ; Chemoresistance / Dihydropyrimidine dehydrogenase / Ortate phosphoribosyltransferase / Thymidylate synthase
  •  go-up   go-down


Advertisement
4. Changchien CR, Wu MC, Tasi WS, Tang R, Chiang JM, Chen JS, Huang SF, Wang JY, Yeh CY: Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining. Dis Colon Rectum; 2004 Nov;47(11):1922-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of prognosis for malignant rectal gastrointestinal stromal tumor by clinical parameters and immunohistochemical staining.
  • PURPOSE: The aim of this study was to identify associated prognostic factors influencing the outcome of curative resection of rectal gastrointestinal stromal tumor.
  • CD44, Bcl-2, P53, and Ki-67 staining were performed on tumors rediagnosed as gastrointestinal stromal tumor for the prognostic evaluation.
  • RESULTS: There were 42 (91.3 percent) patients with rectal gastrointestinal stromal tumor (18 females and 24 males; mean age, 58.4 years).
  • No tumor had a positive P53 stain.
  • Twenty-seven patients (64.3 percent) developed recurrence or metastasis postoperatively (median follow-up, 52 months).
  • The one-year, two-year, and five-year disease-free survival rates were 90.2 percent, 76.7 percent, and 43.9 percent, respectively.
  • Of these patients with recurrence, subsequent resections in 12 patients with local recurrence, transarterial tumor embolism or STI-571 chemotherapies in 3 patients with distant mestastases were performed.
  • The one-year, two-year, and five-year overall survival rates were 97.4 percent, 94.3 percent, and 83.7 percent, respectively.
  • Bcl-2 (P = 0.007) and histologic grade (P = 0.05) in disease-free survival analysis and age < 50 years (P = 0.03) and tumor size > 5 cm (P = 0.02) in overall survival analysis were independent prognostic factors.
  • The group with wide local excision had a higher local recurrence rate than that of the radical resection group (77 percent vs. 31 percent, P = 0.006), despite smaller tumors (4.5 vs. 7.2 cm, P = 0.05).
  • There was no difference in the incidence of distant metastasis between the two groups.
  • CONCLUSION: Younger age (< 50 years), higher histologic tumor grade, positive Bcl-2 status, and larger tumors (> 5 cm) were factors associated with significantly poorer prognoses for rectal gastrointestinal stromal tumor.
  • Radical resection was superior to wide local excision in the prevention of local recurrence, but not that of distant metastases.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Disease-Free Survival. Female. Humans. Immunoenzyme Techniques. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. Proportional Hazards Models. Staining and Labeling. Survival Analysis

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15622586.001).
  • [ISSN] 0012-3706
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Cresswell J, Scheitlin W, Gozen A, Lenz E, Teber D, Rassweiler J: Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience. BJU Int; 2008 Sep;102(7):844-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic retroperitoneal lymph node dissection combined with adjuvant chemotherapy for pathological stage II disease in nonseminomatous germ cell tumours: a 15-year experience.
  • OBJECTIVE: To present our 15-year experience of laparoscopic retroperitoneal lymph node dissection (LRPLND) combined with adjuvant chemotherapy (after RPLND) for patients with nonseminomatous germ cell tumour and positive nodes (pN+), evaluating the morbidity and long-term oncological outcome.
  • PATIENTS AND METHODS: Data for 87 patients with clinical stage I GCT were collected prospectively from 1992 to 2007.
  • Primary diagnostic LRPLND was performed for pathological staging using a modified-template dissection.
  • Patients with lymph node involvement had adjuvant chemotherapy, with two cycles of bleomycin, etoposide and cisplatin.
  • RESULTS: The mean (range) operative duration was 177 (68-360) min, and the hospital stay 6 (4-18) days.
  • Positive nodes were identified in 24% of patients, who subsequently had adjuvant chemotherapy.
  • After a mean (range) follow-up of 84 (1-186) months, distant relapse occurred in 9% of patients with pathological stage I (no adjuvant chemotherapy), including three patients with pulmonary metastases, two with retroperitoneal recurrence (outside the template field), two biochemical recurrences (alpha-fetoprotein elevated) and one port-site metastasis.
  • No patients with pN+ disease relapsed.
  • There were complications after surgery in 9% of patients, i.e. one pulmonary embolus, one lymphocoele, temporary ureteric stenting in two, ureteric stenosis requiring surgical repair in three and retrograde ejaculation in one patient.
  • All patients remain disease-free.
  • CONCLUSIONS: After gaining experience, LRPLND has comparable operative times to contemporary open series, and low morbidity.
  • No patients with pN+ had a recurrence, showing the efficacy of adjuvant chemotherapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Germinoma / therapy. Lymph Node Excision / methods. Retroperitoneal Neoplasms / therapy. Testicular Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Chemotherapy, Adjuvant. Humans. Laparoscopy. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Orchiectomy. Prospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537954.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


6. Ramos M, Benavente S, Giralt J: Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations. Expert Rev Anticancer Ther; 2010 Mar;10(3):339-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of squamous cell carcinoma of the head and neck: updated European treatment recommendations.
  • Risk factors for adjuvant radiotherapy are stage III-IV, perineural involvement or vascular tumor embolism.
  • For patients with nonresectable disease we recommend treatment with concomitant chemoradiation, although this has important acute and late toxicity.
  • Concomitant EGF receptor inhibitors and taxane-based induction chemotherapy are new strategies under study that have demonstrated some benefits but are not yet the standard treatment.
  • Intensity-modulated radiotherapy allows one to decrease radiation dose to organs.
  • Preclinical work in signaling pathways and other oncogenic factors (e.g., human papillomavirus infection) will be the key to improving outcomes of head and neck cancer patients in the future.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Combined Modality Therapy. Europe / epidemiology. Humans. Neoplasm Staging. Practice Guidelines as Topic. Radiotherapy, Adjuvant / adverse effects. Radiotherapy, Adjuvant / methods. Radiotherapy, Intensity-Modulated / methods. Risk Factors

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20214515.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 35
  •  go-up   go-down


7. Madanur MA, Battula N, Azam MO, Heaton N, Rela M: Chylous ascites after pancreatico-duodenectomy cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):416-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of cases do not develop CA, possibly due to patency of the proximal thoracic duct and good collaterals.
  • CA may be due to a consequence of occult obstruction of the proximal thoracic duct by malignant infiltration or tumor embolus.
  • Resolution of CA occurred in these 3 patients at a median follow-up of 4 weeks (range 4-12 weeks).
  • Two patients developed loco-regional recurrences at a median follow up of 8 months (range 6-10 months).
  • And the other was currently disease free at a 10-month follow up.
  • CONCLUSIONS: CA as an uncommon postoperative complication requires frequent paracentesis, prolonged hospital stay, and delayed adjuvant chemotherapy.
  • [MeSH-minor] Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Transplantation. Peritoneum / metabolism. Postoperative Complications. Retrospective Studies

  • Genetic Alliance. consumer health - Chylous Ascites.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690041.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Dzieciuchowicz ŁS, Słowinski M, Brzeziński JJ, Kycler W: Tumor embolus due to uterine cancer. Med Sci Monit; 2009 Oct;15(10):CS155-157
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolus due to uterine cancer.
  • The purpose of this paper is to report a case of tumor embolus of a brachial artery.
  • CASE REPORT: A 64-year-old woman was referred for vascular surgery due to acute right upper-limb ischemia.
  • Because of an atypical appearance resembling fatty tissue, the embolic material was sent for microscopic examination that revealed carcinoma cells.
  • Chest X-ray and CT-guided biopsy showed previously unknown pulmonary metastasis.
  • In spite of chemotherapy, the patient died one year later due to progression of the neoplastic disease.
  • The literature and common features of tumor embolus are reviewed.
  • This may be the first reported case of tumor peripheral arterial embolus caused by endometrial adenocarcinoma CONCLUSIONS: Although tumor emboli are a rarely described cause of acute limb ischemia, pathological examination of the embolic material seems to be indicated, especially in patients with an unknown source of emboli and in every case of an atypical appearance.
  • [MeSH-major] Embolism / complications. Embolism / pathology. Uterine Neoplasms / complications. Uterine Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19789516.001).
  • [ISSN] 1643-3750
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


9. Kosugi M, Ono T, Yamaguchi H, Sato N, Dan K, Tanaka K, Takano T: Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy. Int J Cardiol; 2006 Jul 28;111(1):172-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful treatment of primary cardiac lymphoma and pulmonary tumor embolism with chemotherapy.
  • A 72-year-old man with a large mass in the right atrium and the pulmonary embolism by chest computed tomography was diagnosed as the primary cardiac B-cell lymphoma (PCL) with pulmonary tumor embolism and pericardial effusion.
  • Upon completion of initial chemotherapy, the mass was markedly reduced, and the pulmonary embolism disappeared on magnetic resonance imaging.
  • This rarely diagnosed entity is treatable with chemotherapy for both PCL and pulmonary embolism.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Heart Neoplasms / drug therapy. Lymphoma, B-Cell / drug therapy. Neoplastic Cells, Circulating. Pulmonary Embolism / drug therapy. Pulmonary Embolism / etiology
  • [MeSH-minor] Aged. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Humans. Male. Prednisone / therapeutic use. Remission Induction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Pulmonary Embolism.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16129500.001).
  • [ISSN] 0167-5273
  • [Journal-full-title] International journal of cardiology
  • [ISO-abbreviation] Int. J. Cardiol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] Ireland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


10. Marconnet L, Bouchot O, Culine S, Avances C, Rigaud J, membres du CCAFU-OGE: [Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)]. Prog Urol; 2010 May;20(5):332-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)].
  • [Transliterated title] Prise en charge ganglionnaire dans le carcinome épidermoïde du pénis: revue de la littérature par le comité de cancérologie de l'Association française d'urologie-groupe organes génitaux externes (CCAFU-OGE).
  • The aim of this article is to analyse published research results on the diagnosis and treatment of lymph nodes in cancer of the penis.
  • MATERIAL AND METHOD: Bibliographic research on Medline was carried out using the terms penile carcinoma, lymph node dissection, lymphadenectomy, survival, chemotherapy and radiotherapy.
  • RESULTS: The risk of lymph node metastasis depends on the stage of the primitive tumour, its histological grade, the presence of venous and lymphatic embolus and the presence of palpable lymph nodes (classification into risk groups by the European Association of Urology [EAU]).
  • A diagnosis of suspected adenopathy based on clinical examination associated with FNA biopsy is essential.
  • The search for the sentinel lymph node although interesting remains to be defined, especially in patients who have no palpated adenopathy but are at risk of metastasis.
  • Not only is surgery on inguinal lymph nodes the only reliable way of confirming an invasive metastatic lymph node, it also plays a therapeutic and prognostic role for patients who have a tumour of the penis which risks spreading to lymph nodes (intermediate or high risk according to EAU).
  • The type of dissection is in function with the clinical examination: a radical inguinal dissection is recommended in the case of palpated adenopathy and a modified inguinal dissection is recommended if there is no palpated adenopathy, this should be radicalised in the case of metastatic adenopathy on histological examination.
  • Neo-adjuvant or adjuvant chemotherapy would appear to play a interesting role when combined with surgery for certain patients without there being currently being precise consensus because of the lack of documented cases.
  • The same goes for external radiotherapy on inguinal lymph nodes which seems to play a role in local controls of the lymph node disease though increases morbidity risks of surgical intervention.
  • CONCLUSION: Lymph node dissection alone has a therapeutic role in patients who have reached metastasis of lymph nodes (stage pN1).
  • However, it remains insufficient for patients who have metastatic infiltration of more than 2 lymph nodes (stage > or =pN2).
  • Consequently, it would seem important to develop multimodal approaches in the treatment of these patients in order to increase the rate of response to treatment.
  • [MeSH-minor] Chemotherapy, Adjuvant. France. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Societies, Medical. Urology

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20471577.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


11. Tanoue Y, Tanaka N, Suzuki Y, Hata S, Yokota A: A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism. World J Gastroenterol; 2009 Jan 14;15(2):248-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case report of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein tumor embolism.
  • We report a case of endocrine cell carcinoma in the sigmoid colon with inferior mesenteric vein (IMV) tumor embolism.
  • We performed colonoscopy, computed tomography and positron emission tomography, which disclosed sigmoid colon cancer with IMV tumor embolism.
  • The tumor was diagnosed as endocrine cell carcinoma (type 4, pSS, med, INFalpha, v3, n1, stage IIIb).
  • She was treated with chemotherapy of cisplatin (CDDP) + irinotecan (CPT11).
  • This case highlights the aggressiveness of endocrine cell carcinoma with tumor embolism, and it is essential to establish an accurate diagnosis and effective treatment.

  • Genetic Alliance. consumer health - Embolism.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 1999 Dec;81(8):1351-5 [10604732.001]
  • [Cites] N Engl J Med. 2002 Jan 10;346(2):85-91 [11784874.001]
  • [Cites] Gastric Cancer. 2003;6(4):203-9 [14716513.001]
  • [Cites] Dis Colon Rectum. 2004 Feb;47(2):163-9 [15043285.001]
  • [Cites] Cancer Res. 1983 May;43(5):2088-93 [6187442.001]
  • [Cites] Surg Today. 2007;37(11):989-94 [17952533.001]
  • [Cites] Am J Clin Pathol. 1991 Mar;95(3):315-21 [1847579.001]
  • [Cites] Cancer. 1991 Jul 15;68(2):227-32 [1712661.001]
  • [Cites] Pathol Int. 1995 Aug;45(8):605-9 [7496507.001]
  • [Cites] South Med J. 1996 Sep;89(9):921-4 [8790320.001]
  • [Cites] Cancer. 1990 Jan 1;65(1):135-40 [2293859.001]
  • (PMID = 19132778.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2653316
  •  go-up   go-down


12. Grass H, Schuff A, Staak M, Dienes HR, von Both I: Tumor embolism as a cause of an unexpected death: a case report. Pathol Res Pract; 2003;199(5):349-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Tumor embolism as a cause of an unexpected death: a case report.
  • The primary causes of deaths for individuals with rare cancers can be difficult to diagnose clinically.
  • This study analyzes the death of a 45-year-old woman who reportedly died from an acute pulmonary dysfunction.
  • The autopsy revealed a bulky thyroid tumor with venous invasion, leading to a massive pulmonary tumor embolism.
  • Furthermore, microscopy identified the tumor as a rare pleomorphic myxoid sarcoma.
  • Thus, the patient died of a large pulmonary tumor embolism originating from this rare sarcoma, and not of acute pulmonary dysfunction of any other means.
  • [MeSH-major] Cause of Death. Neoplastic Cells, Circulating / pathology. Pulmonary Embolism / etiology. Sarcoma / pathology. Thyroid Neoplasms / pathology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Female. Humans. Middle Aged. Pneumonia / complications. Pneumonia / drug therapy


13. Ishiko T, Doi K, Beppu T, Hirota M, Ogawa M: [A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy]. Gan To Kagaku Ryoho; 2002 Nov;29(12):2416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of advanced huge hepatocellular carcinoma (H.C.C.) accompanied by tumor embolism to the inferior caval vein (Vv3) that was treated with surgical extended right lobectomy after multimodal therapy].
  • We performed multimodal therapy for a huge hepatocellular carcinoma with tumor embolism (Vv3), for which excision was judged impossible.
  • After treatment, a hepatectomy to the primary lesion was finally carried out and long-term survival was achieved.
  • A 52-years-old man with right lateroabdominal pain had a huge occupied hepatocellular carcinoma that was detected in October 2000.
  • A tumor embolism, which invaded the inferior vena cava, was also seen.
  • A percutaneous transhepatic portal embolism (PTPE) was carried out against the right portal vein to increase in the left lobe capacity.
  • The chemo-radiotherapy (36 Gy to the right hepatic vein and systemic administration of CDDP) and transcatheter arterial chemoembolization were added to the feeding arteries of the hepatic tumor.
  • When a decrease in the postcaval vein tumor embolism was observed, the extended right hepatic lobectomy was performed.
  • The postoperative course was good, and the patient was discharged from the hospital on postoperative day 41.
  • Though lung metastasis and new lesions in left lobe were seen in a recurrence, two years and ten months since the start of the systemic chemotherapy.
  • This case suggested that even if a huge liver cancer with vascular invasion is judged impossible to excise, multimodal therapy with the aim of surgical treatment helps retain the possibility to later chose hepatectomy for the primary lesion and improve prognosis.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Hepatectomy. Liver Neoplasms / therapy. Neoplastic Cells, Circulating / pathology
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Embolization, Therapeutic. Humans. Male. Middle Aged. Vena Cava, Inferior / pathology

  • Genetic Alliance. consumer health - Embolism.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12484089.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin
  •  go-up   go-down


14. Tucakovic M, Bascom R, Bascom PB: Pulmonary medicine and palliative care. Best Pract Res Clin Obstet Gynaecol; 2001 Apr;15(2):291-304
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant pleural effusion is a poor prognostic factor: management options include repeated thoracentesis, chemical pleurodesis, symptomatic relief of dyspnoea with oxygen and morphine, and external drainage.
  • Parenchymal metastases are typically multifocal and respond to chemotherapy, with a limited role for pulmonary metastatectomy.
  • Pulmonary tumour embolism is frequently associated with lymphangitic carcinomatosis, and is most common in choriocarcinoma.
  • Thromboembolic disease, associated with the hypercoagulable state of cancer, is treated with anticoagulation.
  • Inferior vena cava filter placement is indicated when anticoagulation cannot be given, or when emboli recur despite adequate anticoagulation.
  • Opiates are effective at relieving dyspnoea associated with effusions, metatases, and lymphangitic tumour spread.
  • Non-pharmacological therapies include energy conservation, home redesign, and dyspnoea relief strategies, including pursed lip breathing, relaxation, oxygen, circulation of air with a fan, and attention to spiritual suffering.
  • Identification and treatment of gastroesophageal reflux, sinusitis, and asthma can improve many patients' coughs.
  • Chest wall pain responds to local radiotherapy, nerve blocks or systemic analgesia.
  • Case examples illustrate ways to address quality of life issues.
  • [MeSH-major] Genital Neoplasms, Female / complications. Genital Neoplasms, Female / therapy. Lung Diseases / etiology. Palliative Care / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Airway Obstruction / therapy. Cough / therapy. Dyspnea / therapy. Female. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / secondary. Lung Neoplasms / therapy. Meige Syndrome / surgery. Pleural Effusion, Malignant / therapy. Pulmonary Embolism / diagnosis. Pulmonary Embolism / drug therapy. Quality of Life. Vena Cava Filters

  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2001 Harcourt Publishers Ltd.
  • (PMID = 11358403.001).
  • [ISSN] 1521-6934
  • [Journal-full-title] Best practice & research. Clinical obstetrics & gynaecology
  • [ISO-abbreviation] Best Pract Res Clin Obstet Gynaecol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 65
  •  go-up   go-down


15. Klepacka T, Woźniak W, Liebhart M, Michalak E, Kuczabski M, Rychłowska M: [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases]. Med Wieku Rozwoj; 2000 Apr-Jun;4(2 Suppl 2):67-76
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Local recurrences after salvage operations in the therapy of osteogenic sarcoma cases - an analysis of adverse effects based on studied cases].
  • Therapeutic approach in osteogenic sarcoma until 1982 was connected mainly with surgery.
  • Introduction of chemotherapy to the therapeutic protocols of osteogenic sarcoma improved the 5 years survival of patients with osteogenic sarcoma from 20% to 60-70%.
  • The approach to surgical treatment was also changed.
  • The principle of this treatment is usually to perform an operation to spare the limb with an intraoperative frozen section examination of bone marrow.
  • In our Institute during the last 14 years about 300 cases were diagnosed, out of which about 200 were treated surgically, among these about 50% underwent treatment by salvage operations.
  • Only in 7 cases local recurrences of disease were confirmed.
  • Five of these cases were tumours of distal metaphysis of the femur, one case of proximal metaphysis of the tibia and one case of proximal metaphysis of the humeral bone.
  • The sex range M/F was: 5/2, the average age of onset about 14 years.
  • Various factors playing a role in therapeutic adversities were analysed.
  • Among these were: radical surgery, grade of differentiation of the tumour, histological subtype, soft tissue infiltration, reaction to preoperative therapy and the type of chemotherapy.
  • The conducted analysis indicates the role played by sparing surgery in adversities in therapy (3 cases).
  • Attention was also given to the distinct tendency of osteogenic sarcoma to produce vascular embolism which is a source of haematogenously spreading metastases.
  • In 7 cases vascular tumour embolism caused the appaerance of metastatic focuses adjacent to the primary tumour.
  • A certain role in therapeutic adverities is played by the lack of response to preoperative chemotherapy (4/7 cases).
  • [MeSH-major] Bone Neoplasms / surgery. Neoplasm Recurrence, Local. Osteosarcoma / surgery. Salvage Therapy / adverse effects
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Child. Female. Humans. Male. Risk Factors

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11178330.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down






Advertisement